Calcium Channel Blocker Adverse Events in FAERS: 619,000 Reports and Class-Wide Signals

Calcium channel blockers (CCBs) represent one of the most widely prescribed therapeutic classes in modern cardiovascular medicine. Used by tens of millions of patients in the United States alone—with amlodipine routinely ranking as the single most frequently dispensed prescription medication in the country—CCBs are first-line agents for hypertension, chronic stable angina, vasospastic angina, and certain cardiac arrhythmias. Because of this massive patient exposure, postmarketing safety data provide an extensive epidemiological footprint. Across the public openFDA FDA Adverse Event Reporting System (FAERS) database (aggregating over 20.3 million reports, export dated June 8, 2026), calcium channel blockers account for a cumulative total of 619,199 reports. This pharmacovigilance analysis provides clinical safety directors, pharmacy and therapeutics (P&T) committees, and medical-affairs teams with a detailed, data-driven baseline of CCB safety signals, separating the vasodilatory signals of dihydropyridines (DHPs) from the electrophysiological and gastrointestinal profiles of non-dihydropyridines (non-DHPs).

Quick answer

What is the scenario question? A pharmacy & therapeutics committee wants population-level evidence on calcium channel blocker tolerability signals across the class—what does the public FAERS extract actually show, and how do DHP (amlodipine, nifedipine) versus non-DHP (verapamil, diltiazem) agents differ?

Direct Answer: Across the public openFDA FAERS extract (20,328,575 total reports, export dated June 8, 2026), calcium channel blockers (any-role named, 1986–2026) account for 619,199 reports—75.0% serious and 11.0% fatal—overwhelmingly driven by amlodipine (all salts), with nifedipine and diltiazem the next most-named. The most-reported reactions are fatigue (32,427), dyspnoea (30,555), diarrhoea (30,007), drug ineffective (29,265), nausea (26,226), dizziness (25,578) and hypotension (17,828), and the leading indication is hypertension (143,870). The clinical profile reflects a clear pathophysiological split: DHPs dominate vasodilatory reports (peripheral edema, headache, flushing, reflex tachycardia), whereas non-DHPs concentrate conduction-system blockages (bradycardia, AV block) and severe constipation.

*Note: 2026 data are partial, reflecting reporting processed through the June 8, 2026 snapshot. These figures must not be annualized.

---

Who this is for

• Pharmacovigilance and Safety Teams: Establishing quantitative class baselines to help differentiate background safety noise from true safety alerts.
• P&T Committee Members and Formulary Managers: Reviewing real-world safety data to design evidence-based step-therapy protocols and class exclusions for cardiovascular drugs.
• Medical Affairs and Medical Information Specialists: Preparing dossiers, AMCP summaries, and clinical safety briefs regarding drug-specific vs. class-wide risks.
• Specialty Pharmacists and Clinical Directors: Structuring monitoring workflows for patients on high-risk CCB combinations, IV formulations, or specialized delivery systems.

---

Methodology, in one paragraph

The statistics presented in this analysis are computed directly from the public openFDA FAERS extract (export dated June 8, 2026), representing 20,328,575 total reports. Calcium channel blockers are identified when the drug substance name matches generic identifiers and brand names for the primary agents in the class: amlodipine (including besylate, base, benzoate, and maleate salts), nifedipine, diltiazem (hydrochloride), verapamil (hydrochloride), felodipine, nicardipine, nimodipine, nisoldipine, isradipine, and clevidipine. Report counts are normalized by unique safety report IDs to prevent duplicate counting. Seriousness categories are derived from the FDA’s standardized flags (serious, fatal, hospitalization). Adverse events are mapped to MedDRA Preferred Terms (PTs). Because FAERS is a spontaneous-reporting system, these figures represent raw reporting frequencies rather than incidence rates. They lack an exposure denominator (total patient-years), are subject to reporting biases, and do not establish direct clinical causality. For broader database methodology, see our companion inside 20 million FAERS reports; for cardiovascular comparisons, see our analyses of ACE inhibitor and ARB adverse events by the numbers and beta-blocker adverse events by the numbers.

---

How many FAERS adverse-event reports name a calcium channel blocker, and how serious are they?

Historically, the cumulative volume of reports naming a CCB in any role (primary suspect, secondary suspect, concomitant, or interacting) has remained remarkably high, reflecting the class's status as a cornerstone of cardiovascular therapy. Over the full span of the FAERS database (1986 through mid-2026), the class has accumulated 619,199 reports.

Of these, 464,137 reports (75.0%) are classified as serious (resulting in death, hospitalization, life-threatening events, disability, or requiring significant medical intervention). A total of 67,850 reports (11.0%) carry a fatal outcome flag.

Evaluating the annual trend over the last decade shows a highly stable reporting volume. Reporting peaked in 2019 with 48,072 reports, followed by a moderate stabilization. In 2024, the class accumulated 34,947 reports, and in 2025 it ran 35,471 reports. The partial data for 2026 (8,832 reports through June 8) indicates that the annual run-rate remains on target for approximately 35,000 reports.

Annual Named Reports (2015-2025):
2015: 34,622
2016: 37,549
2017: 39,121
2018: 45,531
2019: 48,072 (Peak)
2020: 44,268
2021: 40,321
2022: 39,253
2023: 37,321
2024: 34,947
2025: 35,471

This stable pattern reflects a mature class where safety profiles are well-understood. Unlike newer oncology or immunology classes, where sudden spikes are driven by new approvals and "stimulated" reporting, CCB reporting is driven by stable, long-term prescribing volumes.

Importantly, the high proportion of serious reports (75.0%) and deaths (11.0%) is an epidemiologic feature of spontaneous surveillance, not an indicator of intrinsic toxicity. Because these drugs are primarily used in older, multimorbid patients with severe cardiovascular disease (e.g., severe hypertension, advanced coronary artery disease, heart failure, atrial fibrillation), many reported deaths and hospitalizations represent background clinical events (such as strokes, myocardial infarctions, or progression of renal failure) that are reported because the patient was taking a CCB at the time of the event.

---

Which CCB drives the most reports — amlodipine, nifedipine, diltiazem or verapamil?

The distribution of reports among individual CCB substances is heavily skewed toward amlodipine. Token-level analysis of the generic substances reported in the database demonstrates the overwhelming dominance of amlodipine salts:

• Amlodipine Besylate: 431,214 reports
• Amlodipine (Base): 263,104 reports
• Amlodipine Benzoate: 262,953 reports
• Nifedipine: 37,454 reports
• Diltiazem Hydrochloride: 31,304 reports
• Felodipine: 10,154 reports
• Nicardipine Hydrochloride: 3,359
• Verapamil Hydrochloride: 3,277
• Nimodipine: 990
• Nisoldipine: 942
• Clevidipine: 358

(Note: Token-level counts overlap because a single case report can list amlodipine under multiple synonyms or salt forms, particularly in combination products. These figures must not be summed).

Amlodipine (across all salt forms) accounts for approximately 75% of all reports within the class — 464,201 of the 619,199 deduplicated class reports — a concentration that mirrors its prescribing dominance rather than flagging an intrinsic class signal. To interpret this concentration, access and safety teams must distinguish between a drug's intrinsic safety signal and its prescribing volume. Amlodipine is the most prescribed antihypertensive in the US, with over 75 million active prescriptions annually. Its dominance in FAERS is a direct reflection of this massive clinical exposure (the "denominator effect") rather than a sign that amlodipine is less safe than nifedipine or diltiazem.

Nifedipine stands as the second most reported DHP agent (37,454 reports), reflecting its extensive use in extended-release formulations for chronic hypertension and angina, as well as its acute use in obstetric settings for preeclampsia. Among non-DHP agents, diltiazem hydrochloride (31,304 reports) is significantly more common in the database than verapamil hydrochloride (3,277 reports), reflecting its preferred status in clinical algorithms for rate control in atrial fibrillation and its lower rate of severe constipation compared to verapamil.

---

What are the top reported reactions, and how do DHP vs non-DHP signals separate?

Analyzing the overall reaction terms for reports naming a calcium channel blocker highlights a mixture of clinical side effects, general safety events (such as falls), and indicators of disease progression:

Top 20 Reported Reactions (Class-Wide, Cumulative):
1. Fatigue: 32,427
2. Dyspnoea (Shortness of breath): 30,555
3. Diarrhoea: 30,007
4. Drug ineffective: 29,265
5. Nausea: 26,226
6. Dizziness: 25,578
7. Headache: 21,427
8. Asthenia (Weakness): 21,092
9. Off label use: 20,801
10. Death: 19,071
11. Fall: 18,537
12. Hypotension: 17,828
13. Arthralgia: 17,060
14. Acute kidney injury: 16,610
15. Hypertension: 16,475
16. Pain: 16,406
17. Malaise: 16,176
18. Blood pressure increased: 15,508
19. Pneumonia: 15,084
20. Cough: 14,725

Within these class-wide aggregates, we must apply pathophysiological rules to separate DHP and non-DHP signals. The two sub-classes have fundamentally different mechanisms of action and, consequently, distinct safety profiles.

1. Dihydropyridines (DHP): Vasodilatory Signals

DHP agents (amlodipine, nifedipine, felodipine) bind selectively to L-type calcium channels in vascular smooth muscle, causing potent arterial vasodilation. This mechanism is highly effective for reducing systemic vascular resistance, but it directly causes:

• Peripheral Edema: This is the signature adverse effect of DHP CCBs, appearing as fluid accumulation in the lower extremities. It is caused by precapillary vasodilatation, which increases capillary hydrostatic pressure and leads to fluid extravasation into the interstitial space. It is not associated with renal or cardiac dysfunction. In clinical trials, the incidence of amlodipine-induced peripheral edema is dose-dependent, reaching up to 16.6% in a 2019 meta-analysis of randomized controlled trials at the 10 mg daily dose. In FAERS, peripheral edema terms are tightly clustered around the DHP suspects.
• Headache and Dizziness: Rapid arterial vasodilation can cause transient cerebral vasodilation, resulting in headaches (21,427 reports class-wide) and orthostatic dizziness (25,578 reports).
• Reflex Tachycardia: Because DHPs do not depress cardiac conduction, the rapid drop in blood pressure can trigger a sympathetic baroreceptor reflex, resulting in reflex tachycardia (particularly with short-acting nifedipine formulations).

2. Non-Dihydropyridines (Non-DHP): Conduction and GI Signals

Non-DHP agents (diltiazem, verapamil) bind to L-type calcium channels in both vascular smooth muscle and cardiac tissues, with a much higher affinity for cardiac muscle than DHPs. They exert negative inotropic (reduces contractility), negative chronotropic (reduces heart rate), and negative dromotropic (slows nodal conduction) effects. Their safety profile in FAERS is characterized by:

• Conduction Disturbances (Bradycardia and AV Block): By depressing the sinoatrial (SA) and atrioventricular (AV) nodes, non-DHPs can precipitate severe bradycardia, sinus arrest, or second- and third-degree AV block. These reports are highly concentrated in the diltiazem and verapamil subsets.
• Constipation: Constipation is a classic, dose-dependent side effect of verapamil, affecting up to 11% of patients in clinical trials. It occurs because verapamil inhibits calcium-dependent contractions of the colonic smooth muscle, reducing peristalsis. While often considered a minor side effect, severe cases in older adults can lead to fecal impaction, bowel obstruction, or perforation, resulting in hospitalizations that populate the FAERS database.
• Negative Inotropy and Heart Failure Exacerbation: By depressing myocardial contractility, non-DHPs can precipitate acute decompensated heart failure in patients with pre-existing left ventricular systolic dysfunction (ejection fraction < 40%). Consequently, clinical guidelines list systolic heart failure as a contraindication for verapamil and diltiazem.

---

What explains the ~11% fatality share and the 2019 reporting peak?

To understand the 11.0% fatality rate (67,850 deaths) and the 2019 reporting peak (48,072 reports), pharmacovigilance and access teams must analyze the patient population and the history of product quality events:

1. The Fatality Share: Comorbidities and Age

The high proportion of fatal reports in the CCB class is heavily influenced by the baseline risk of the treated population. CCBs are first-line therapies for patients with advanced cardiovascular disease, diabetes, and renal impairment. The top indications and co-medications in the database reflect this high-risk profile:

• Hypertension: 143,870 reports list hypertension as the primary indication.
• Diabetes Mellitus: 27,698 reports.
• Atrial Fibrillation: 22,352 reports.

A significant proportion of these patients suffer from severe coronary artery disease, chronic kidney disease (CKD), or are post-stroke. Consequently, many deaths reported to FAERS represent background cardiovascular events (such as sudden cardiac death, acute coronary syndrome, or stroke) that are reported because the patient was taking a CCB, rather than events caused by the drug itself.

Furthermore, the reporter mix is highly professional, indicating a clinical surveillance profile rather than a litigation-driven one:

• Consumer: 220,940 reports (35.7%)
• Physician: 167,536 reports (27.1%)
• Other Healthcare Professional: 132,481 reports (21.4%)
• Pharmacist: 57,777 reports (9.3%)
• Lawyer: 7,065 reports (1.1%)

Because lawyers account for only ~1.1% of submissions, the database is not inflated by litigation-driven reporting waves, which historically created massive artificial spikes in other classes (such as fluoroquinolones or proton pump inhibitors).

2. The 2019 Peak and the Multiple-Myeloma Co-Prescribing Signal

The class-wide reporting peak in 2019 (48,072 reports) tracks the broader openFDA FAERS extract, whose total reporting volume crested in the 2018–2019 window and then moderated; it is not evidence of a CCB-specific safety event. The most distinctive non-cardiovascular indication inside the class is plasma cell myeloma (multiple myeloma): 26,518 reports — a co-prescribing artifact rather than an oncology signal for CCBs.

Multiple myeloma regimens rely on proteasome inhibitors, especially carfilzomib (Kyprolis), which carries a well-documented risk of treatment-emergent cardiovascular toxicity (severe hypertension, heart failure, and ischemic events). Because clinicians routinely add a DHP CCB — most often amlodipine — to control that hypertension, amlodipine appears as a concomitant drug on a meaningful slice of myeloma safety reports (carfilzomib is co-named with a CCB in roughly 1,100 reports across the database). This signal is genuine and material, but it does not explain the 2019 peak: myeloma reports actually climbed from 2015 through 2021, their own peak year, before declining — a curve that follows the maturing uptake and postmarketing surveillance of carfilzomib-based regimens, not a single-year spike. The practical point for signal-detection teams is to filter oncology co-prescribing out of amlodipine cardiovascular events before attributing any disproportionality to the CCB itself.

---

How do combination products and route affect the class cut?

The CCB class cut is complicated by the extensive use of combination products and specialized routes of administration. Access and clinical safety teams must analyze these factors to avoid misinterpreting database counts:

1. Combination-Product Conflation

Amlodipine is frequently co-formulated with other cardiovascular classes to improve patient adherence. These combination products include:

• Amlodipine-Valsartan (Exforge): Combines a DHP CCB with an Angiotensin II Receptor Blocker (ARB).
• Amlodipine-Lisinopril: Combines a DHP CCB with an ACE inhibitor.
• Amlodipine-Olmesartan (Azor): Combines a DHP CCB with an ARB.
• Amlodipine-Atorvastatin (Caduet): Combines a DHP CCB with a statin.

Because the openFDA substance index parses these combinations at the individual ingredient level, a report naming Exforge will increment the counts for both amlodipine and valsartan. Safety teams must disclose this conflation, as the reported adverse event (such as hyperkalemia or cough) may be entirely driven by the ARB or ACE inhibitor component, yet it will appear in the CCB substance counts.

2. Route of Administration and Indication Distortions

While oral amlodipine and nifedipine are used for chronic hypertension, several CCBs are administered via specialized routes for acute, high-risk indications, creating distinct safety profiles:

• Intravenous Nicardipine and Clevidipine: Used in emergency departments and intensive care units for rapid, short-term blood pressure control (e.g., in hypertensive emergency, acute stroke, or post-operative cardiac surgery). Clevidipine is formulated as a lipid emulsion, carrying specific risks of hypertriglyceridemia and pancreatitis. These IV formulations generate reports characterized by acute hypotension (17,828 class-wide reports) and reflex tachycardia in critical care settings.
• Oral Nimodipine: Used exclusively for the prevention of ischemic deficits following subarachnoid hemorrhage (SAH). Nimodipine is highly lipophilic, allowing it to cross the blood-brain barrier and target cerebral vasculature to prevent vasospasm. Because nimodipine is administered to patients in neuro-ICUs recovering from ruptured cerebral aneurysms, its safety reports are heavily populated by severe neurological events (cerebral vasospasm, hydrocephalus, death) that reflect the underlying SAH pathology rather than drug toxicity. Crucially, the FDA maintains a boxed warning on nimodipine warning against accidental intravenous administration, which can cause severe, life-threatening hypotension and cardiac arrest.

---

What decision rules should a P&T committee take from these signals?

For pharmacy and therapeutics (P&T) committees, formulary managers, and clinical safety directors, the real-world safety data in FAERS support several actionable clinical decision rules:

1. Managing the CCB Overdose Toxidrome

P&T committees must ensure that emergency departments and intensive care units have clear clinical protocols for managing CCB overdose. While CCBs are safe at therapeutic doses, overdose carries a very high mortality rate.

• Pathophysiology: Overdose causes profound systemic vasodilation (DHP effect) and cardiogenic shock due to severe myocardial depression, bradycardia, and nodal block (non-DHP effect).
• L-Type Channel Selectivity Loss: Crucially, at high toxic doses, the selectivity of DHP CCBs is lost. An overdose of amlodipine will cause severe myocardial depression and bradycardia similar to verapamil, resulting in refractory shock.
• Metabolic Distortions: CCB overdose inhibits L-type calcium channels in pancreatic islet cells, reducing insulin secretion and causing severe hyperglycemia.
• Treatment Protocol: Emergency protocols must include intravenous calcium (to override channel blockade), high-dose insulin euglycemia therapy (HIET, to support myocardial carbohydrate metabolism), vasopressors (norepinephrine), and lipid emulsion therapy for lipophilic agents (verapamil, diltiazem).

2. Managing the Grapefruit-CYP3A4 Interaction

P&T committees and clinical pharmacists must enforce electronic health record (EHR) alerts for drug-drug interactions involving non-DHP CCBs.

• Mechanism: Verapamil and diltiazem are moderate-to-strong inhibitors of the CYP3A4 enzyme and the P-glycoprotein (P-gp) efflux transporter.
• Grapefruit Juice: Grapefruit juice contains furanocoumarins, which irreversibly inhibit intestinal CYP3A4. Co-administration of grapefruit juice with oral verapamil or diltiazem can increase their bioavailability by 2- to 3-fold, precipitating severe hypotension, bradycardia, and AV block.
• Statin Interactions: Verapamil and diltiazem significantly increase plasma concentrations of CYP3A4-metabolized statins (simvastatin, atorvastatin, lovastatin), increasing the risk of statin-induced myopathy and rhabdomyolysis. EHR systems should restrict simvastatin doses to a maximum of 10 mg daily when co-prescribed with verapamil or diltiazem, or guide clinicians to switch to non-CYP3A4 statins (rosuvastatin, pravastatin).
• DOAC Interactions: Non-DHPs increase the exposure of P-gp substrate direct oral anticoagulants (such as dabigatran and apixaban), requiring dose adjustments or intense bleeding monitoring.

3. Clinically Gating the DHP-to-non-DHP Switch

Formulary guidelines should enforce strict clinical check-points before allowing a patient to switch between CCB sub-classes:

• The Edema Misconception: If a patient on amlodipine develops peripheral edema, the edema is a local mechanical effect (precapillary dilation) and does not indicate heart failure. Clinicians must not treat amlodipine edema with loop diuretics (such as furosemide), which is an ineffective and high-risk practice (leads to volume depletion and AKI). Instead, the dose of amlodipine should be reduced, or an ACE inhibitor/ARB should be added (which dilates the postcapillary venule, normalizing hydrostatic pressure), or the patient should be switched to a non-DHP CCB.
• The Heart Failure Gate: Before switching a patient from amlodipine to verapamil or diltiazem to resolve edema or manage atrial fibrillation, the clinician must confirm that the patient does not have heart failure with reduced ejection fraction (HREF). Initiating a non-DHP in this population can precipitate acute cardiogenic shock.

---

What this means for pharmacovigilance, medical-affairs, and access teams

• Adjust for the Denominator in Signal Detection: Pharmacovigilance teams running disproportionality analyses (such as Reporting Odds Ratios) must adjust for amlodipine's massive prescription volume. Raw report counts (e.g., 431,214 for amlodipine besylate) must not be interpreted as a higher risk profile compared to diltiazem (31,304 reports) or nifedipine (37,454 reports).
• Disentangle Concomitant Chemotherapy Signals: When analyzing cardiovascular deaths or heart failure signals in amlodipine reports, safety teams must filter out oncology co-prescriptions (such as carfilzomib for multiple myeloma). These oncology-stimulated reports represent a significant source of database noise that can distort cardiovascular safety signals.
• Provide Evidence-Based Medical Information: Medical affairs teams can utilize the DHP vs. non-DHP suspect splits in FAERS to support clinical safety responses. Highlighting that peripheral edema is a localized DHP vasodilatory event while bradycardia and constipation are cardiac/muscular non-DHP events helps clinicians select the appropriate agent based on patient-specific risk factors.
• Align Formulary step-therapy with Safety Profiles: Formulary managers can use the safety differences to structure step-therapy rules. Generic DHPs (amlodipine) should remain the primary step-1 option due to their broad cardiac safety (lack of negative inotropy/nodal depression), reserving non-DHPs (diltiazem) as step-2 options for specific indications like atrial fibrillation, while enforcing interaction blocks for CYP3A4 inhibitors.

---

FAQs

Does FAERS prove that calcium channel blockers cause peripheral edema or bradycardia?

No. FAERS records adverse events that occurred while a patient was taking a medication, but a report does not establish that the drug caused the event. Spontaneous reports are subject to major limitations, including incomplete data, variable reporter training, and duplicate submissions.

Because FAERS lacks a control group and a prescribing denominator (total exposed patients), it is impossible to calculate the absolute incidence of an event from FAERS data alone. Causal proof requires controlled clinical trials and prospective observational studies. However, the strong clustering of peripheral edema around DHP agents and bradycardia around non-DHP agents in FAERS aligns with the established mechanisms of action.

Why is amlodipine so far ahead of every other CCB in FAERS report count?

Amlodipine's overwhelming dominance in the database (accounting for approximately 75% of the class reports) is driven by the "denominator effect." Amlodipine is the most prescribed calcium channel blocker and one of the most prescribed drugs in the world, with over 75 million active prescriptions in the US.

Because safety reports are generated in proportion to a drug's clinical exposure, a highly prescribed drug will naturally generate a large number of reports, even if its rate of adverse events is low. Amlodipine's high report count reflects its massive prescribing volume, not a higher risk profile compared to other CCBs.

Is the 11.0% death figure a sign that CCBs are unusually dangerous?

No. The 11.0% fatality rate in reports naming a CCB reflects the characteristics of the patient population and the nature of spontaneous reporting. CCBs are primarily prescribed to older adults with serious cardiovascular diseases, including advanced hypertension, coronary artery disease, and heart failure.

These patients have a high baseline mortality rate due to cardiovascular events like strokes and myocardial infarctions, independent of drug therapy. In spontaneous reporting, minor side effects are underreported, while severe events like death or hospitalization are highly likely to be reported. The deaths recorded are background events occurring in a high-risk population, not events caused by the medication.

How does the CCB class compare in size to other cardiovascular classes in the FAERS series?

The calcium channel blocker footprint in FAERS (619,199 reports) represents one of the largest cardiovascular class cuts in the database, reflecting its extensive prescribing volume. It is comparable in size to the renin-angiotensin-aldosterone system (RAAS) blocker class (which includes ACE inhibitors and ARBs) and the beta-blocker class, which also generate hundreds of thousands of reports due to their status as first-line chronic cardiovascular therapies.

In contrast, specialized cardiovascular classes (such as direct oral anticoagulants or pulmonary arterial hypertension therapies) generate smaller cumulative report volumes due to their narrower indications and lower prescribing denominators.

---

Sources

• US FDA. openFDA FAERS (Adverse Event Reporting System) extract, export dated June 8, 2026. Per-drug, class-union, and reaction aggregates computed by PharmaDossier from the public FAERS extract. openFDA Data
• U.S. National Library of Medicine. "Calcium Channel Blockers." StatPearls. NCBI Bookshelf. Last updated January 2026. NCBI Bookshelf
• Vukadinović D, Böhm M, Volpe M, et al. "Peripheral edema and headache associated with amlodipine treatment: a meta-analysis of randomized controlled trials." Journal of Hypertension. 2019;37(10):1903-1911. PubMed
• Russell RP. "Side effects of calcium channel blockers." Journal of Clinical Pharmacology. 1988;28(3):272-277. PubMed
• U.S. FDA. "FDA approves first generics of Eliquis (apixaban)." FDA Drug Safety Communications. (Cross-class cardiovascular safety comparisons). FDA Portal
• U.S. FDA. Drugs@FDA Database. Prescribing Information for Norvasc (amlodipine besylate), Cardizem (diltiazem hydrochloride), and Calan (verapamil hydrochloride). Drugs@FDA